Age-related Macular Degeneration Market Size, Share & Trends Analysis Report By Product (Eylea, Lucentis, Beovu), By Disease Type (Wet AMD, Dry AMD), By Distribution Channel, By Region- Global Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2022-2030

According to Nova one advisor, the global Age-related Macular Degeneration market size was estimated at USD 10.40 billion in 2022 and is projected to hit around USD 18.29 billion by 2030, growing at a CAGR of 6.70% during the forecast period 2022 to 2030.

Key Takeaways:

• By product, eylea accounted for the largest revenue share in 2021 owing to the higher market penetration and patent protection. Beovu is anticipated to be the fastest-growing segment over the forecast period due to patent protection and superior drying efficacy
• By disease type, wet AMD held the largest share in 2021 owing to the availability of major anti-VEGF products including Eylea, Lucentis, and Beovu
• North America held the largest market share in 2021 and is expected to dominate over the forecast period due to better reimbursement facilities and the high adoption of novel age-related macular degeneration drugs for the treatment
• Based on distribution channel, specialty pharmacy is expected to be the fastest-growing segment during the forecast period owing to increasing collaboration of manufacturers with specialty pharmacies for distributing their products

The growth is due to high R&D investments for new product development, product launches, rising age-related macular degeneration (AMD) prevalence, and the rising geriatric population.

Among wet (exudative) and dry (atrophic) age-related macular degeneration, dry AMD is a more prevalent eye disease with 85-90% of cases causing vision damage due to excessive drusen development in the retina. National Eye Institute statistics suggest that the prevalence of advanced age-related macular degeneration in the U.S. was approximately 3 million in 2020.

There are no approved drugs available yet to treat dry age-related macular degeneration. This creates an opportunity for market players to address the unmet medical needs of dry AMD patients. However, for wet AMD, anti-VEGF drugs are used to treat and control the further deterioration of the condition.

Patients tend to discontinue their treatment without completion owing to frequent clinic visits and administration of drugs at shorter intervals. The key players are engaged in the research & development of longer acting anti-VEGF products to address the increased demand for such products. In February 2020, Novartis AG received approval for its product, Beovu, a macular degeneration drug from the European Commission for the treatment of patients with age-related macular generation. It is a long-acting drug to be administered at an interval of 12 weeks for the first year.

In addition, F. Hoffmann-La Roche Ltd.’s drug candidate, Vabysmo (faricimab), with an injection administration period of 4 weeks during loading dose; received U.S. FDA approval in January 2022 for the treatment of age-related macular degeneration. Furthermore, in October 2021, Roche’s Susvimo received FDA approval and is expected to enter the U.S. in 2022. It is a refillable implant specific for LUCENTIS administration, with a refillable duration of six months. All these factors are expected to propel the market growth over the forecast period.

The patent expiry year for EYLEA is 2023 in the U.S. and 2025 in Europe, depending upon several patent categories. Lucentis (F. Hoffmann La Roche Ltd.) lost its patent in June 2020 in the U.S. and will lose patent protection in 2022 in Europe. As a result, biosimilar manufacturing companies are leveraging the opportunity to penetrate the AMD market. For instance, in October 2021, Formycon AG and Bioeq AG received the U.S. FDA acceptance of BLA for the company’s biosimilar version of Lucentis. The PDUFA date for the review of the application is scheduled for August 2022. All these factors could hamper the market growth over the forecast period.

Report Scope of the Age-related Macular Degeneration Market

Report Coverage	Details
Market Size	USD 18.29 Billion by 2030
Growth Rate	CAGR of 6.70% from 2022 to 2030
Largest Market	Asia Pacific
Fastest Growing Market	North America
Base Year	2021
Forecast Period	2022 to 2030
Segments Covered	Product, disease type, distribution channel and Region,
Companies Mentioned	F. Hoffmann-La Roche Ltd.; Novartis AG; Bayer AG; Pfizer Inc.; Bausch Health Companies Inc.; Regeneron Pharmaceuticals Inc.; Amgen Inc.; Biogen; Samsung Bioepis

Product Insights

The eylea segment dominated the market in 2022 with a revenue share of over 51.9%. This dominance can be attributed to high market penetration and patent protection. In addition, according to research studies, patients receiving Beovu reported four times more intraocular inflammation than those on Eylea. Such factors boost the adoption of Eylea over the novel drug Beovu. Followed by Eylea, Lucentis is expected to hold the largest market share over the coming years owing to factors such as the launch of a new drug delivery system. In October 2021, F. Hoffmann La Roche Ltd.’s product Susvimo, which is a refillable implant for Lucentis, obtained U.S. FDA approval. Susvimo requires refilling with ranibizumab once in six months. This will decrease the frequency of administration, thus addressing the unmet need of patients.

Beovu is anticipated to witness the fastest growth over the forecast period owing to the patent protection, superior drying efficacy, and positive results in the treatment of severe cases of wet AMD. However, the product has been found to be associated with concomitant vascular occlusion, retinal vasculitis, intraocular inflammation, and irreparable vision loss in patients. Due to these serious adverse effects, the sales of the product may be affected in the coming years if the company does not introduce an innovative approach to avoid or reduce these adverse reactions.

Disease Type Insights

The wet AMD segment dominated the market in 2022 with a revenue share of 100%. nAMD accounts for more than 10-15% of macular degeneration-related vision loss cases across the globe. Lucentis, Eylea, and Beovu are the major drugs approved for the treatment of wet age-related macular degeneration. Novartis’ Beovu, a long-acting anti-VEGF, was approved by the U.S. FDA in October 2019. However, the unfavorable side effects of this drug, such as retinal vasculitis, will limit its broader uptake.

Dry AMD is anticipated to witness the fastest growth over the forecast period owing to the expected launch of promising product candidates by 2023 and the disease burden of dry AMD. Dry AMD accounts for 85-90% of all macular degeneration cases. The management of dry macular degeneration is currently limited to vitamin formulations. Various novel therapeutic options for its treatment are currently in the clinical pipeline such as Luminate, Zimura, and Intravitreal pegcetacoplan. The approval of these potential candidates may fuel the growth of the dry AMD segment in the coming years.

Distribution Channel Insights

The hospital pharmacy segment dominated the global market in 2021 with a revenue share of over 51.0%. This dominance can be attributed to the rise in the prevalence of age-related macular degeneration (AMD) and hospitalization for the treatment. According to the Royal National Institute of Blind People (RNIB), around 25.3 million people were at high risk of developing age-related macular degeneration (AMD) in 2020. The majority of patients are treated by using various medications such as Lucentis, Eylea, and Beovu, which are administrated intravenously under the supervision of experienced physicians in hospitals. Thus, increasing demand for AMD treatment is anticipated to increase hospital visits, thereby driving the market.

The specialty pharmacy segment is expected to witness the fastest growth over the forecast period due to the ease of drug availability and reimbursement coverage offered by specialty pharmacies. For instance, CVS Caremark offers Eylea, Lucentis, Avastin, and Beovu prescription coverage to eligible retirees and employees who are enrolled in the Public Employees Insurance Program (PEIP) program. This initiative is expected to fuel segment growth.

Regional Insights

North America dominated the market in 2022 with a revenue share of over 51.0%. This dominance can be attributed to the increasing prevalence of AMD. According to the American Academy of Ophthalmology, around 15 million North Americans live with AMD. Europe held the second-largest market share in 2021. This is due to the high prevalence of macular degeneration in Europe, which is estimated to rise by around 20% until 2050.

Asia Pacific is expected to be the fastest-growing region during the forecast period. The growth of the region can be attributed to the high geriatric population and disease burden. The favorable government initiatives to support the affordability of costly anti-VEGF products may contribute to the market growth. Lucentis and Eylea were added to the National Reimbursement Drug List (NRDL) in China in 2017 and 2019.

Some of the prominent players in the Age-related Macular Degeneration Market include:

• F. Hoffmann-La Roche Ltd.
• Novartis AG
• Bayer AG
• Pfizer Inc.
• Bausch Health Companies Inc.
• Regeneron Pharmaceuticals Inc.
• Amgen Inc.
• Biogen
• Samsung Bioepis

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Age-related Macular Degeneration market

• Product
• Eylea
• Lucentis
• Beovu
• Others
• Disease Type
• Dry AMD
• Wet AMD
• Distribution Channel
• Hospital Pharmacy
• Specialty Pharmacy
• Online Pharmacy

By Geography

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa (MEA)

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Age-related Macular Degeneration industry analysis from 2022 to 2030 to identify the prevailing Age-related Macular Degeneration industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Age-related Macular Degeneration industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Age-related Macular Degeneration industry trends, key players, market segments, application areas, and market growth strategies.